BridgeMD
Heart rate control: Betablockers or Ivabradine therapy before cardiac computed tomography
EU CTIS ID: 2025-522741-21-00
What this study is testing
The primary objective is to determine which type and dose of medication – beta-blockers or ivabradine – most rapidly achieves a ≥10% reduction in heart rate in patients with a resting heart rate above 65 beats per minute undergoing evaluation for asymptomatic or symptomatic ischemic heart disease prior to cardiac CT.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Patients scheduled for a cardiac CT scan. 2. Sinus rhythm with a heart rate > 65 beats per minute documented by ECG. 3. Competent patients who have provided written informed consent.
You likely can't join if
- 1. Age under 30 years 2. Age over 80 years 3. Heart rate greater than 100 bpm 4. BMI greater than 35 5. History of cardiovascular interventions or disease: Percutaneous coronary intervention (PCI, with or without stent), coronary artery bypass grafting (CABG), known ischemic heart disease 6. Pacemaker 7. Acute coronary syndrome (ACS) 8. Known allergy to: Beta-blockers, Ivabradine or administered contrast media 9. Pregnancy or breastfeeding includes potentially pregnant women (pregnancy test required) 10. Heart failure with systolic left ventricular ejection fraction < 45% 11. Impaired renal function: Estimated glomerular filtration rate (eGFR) < 40 ml/min 12. Ongoing treatment with any of the following: Beta-blockers, Ivabradine, Non-dihydropyridine calcium channel blockers (verapamil or diltiazem), Cordarone (amiodarone) 13. Contraindications to beta-blockers or ivabradine, including: Severe asthma, severe chronic obstructive pulmonary disease (COPD), Sick sinus syndrome, Atrioventricular (AV) block (1st, 2nd, or 3rd degree), Hypotension (systolic blood pressure < 110 mmHg), Severe heart failure, Severe restrictive cardiomyopathy, Severe aortic stenosis, Severe circulatory disorders, Certain metabolic conditions, Untreated pheochromocytoma, Concomitant treatment with: Potent CYP3A4 inhibitors, Monoamine oxidase (MAO) inhibitors, CYP2D6 inhibitors, Intravenous calcium channel blockers (type 1 or 2)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.